Christoph Gerlinger1, James Trussell2, Uwe Mellinger3, Martin Merz3, Joachim Marr3, Ralf Bannemerschult3, Ilka Schellschmidt3, Jan Endrikat4. 1. Bayer HealthCare Pharmaceuticals, 13353 Berlin, Germany; Gynecology, Obstetrics and Reproductive Medicine, University Medical School of Saarland, 66421 Homburg/Saar, Germany. Electronic address: christoph.gerlinger@bayer.com. 2. Office of Population Research, Princeton University, Princeton, NJ 08544, USA; The Hull York Medical School, Hull HU6 7RX, UK. 3. Bayer HealthCare Pharmaceuticals, 13353 Berlin, Germany. 4. Bayer HealthCare Pharmaceuticals, 13353 Berlin, Germany; Gynecology, Obstetrics and Reproductive Medicine, University Medical School of Saarland, 66421 Homburg/Saar, Germany.
Abstract
OBJECTIVE: To examine the impact of subject characteristics on efficacy as measured by the Pearl Index (PI) in clinical trials and to make study populations similar by matching. METHODS: Our analysis used US data from four large Phase III studies. We compared results from one fertility control patch study with pooled data from three studies with virtually identical design on oral hormonal contraceptives. First, we identified three characteristics that had the most impact on the PI. Second, we used these three variables and matched subjects from the patch study with those from the oral contraceptive (OC) studies. Finally, we calculated the PIs for matched and unmatched subjects from both the patch study and the OC studies. RESULTS: A total of 3706 subjects were included in our analysis. The variables 'Hispanic ethnicity', 'previous pregnancy' and 'previous use of hormonal contraceptives' had the most impact on the PI. The PIs for the matched patch cohort and the matched OC cohort were 2.97 and 2.48, respectively. Those for the unmatched patch cohort and the unmatched OC cohort were 10.17 and 0.90, respectively. CONCLUSION: Subject characteristics strongly influence the PI in clinical studies of hormonal contraceptives. In particular, Hispanic ethnicity, previous pregnancies and no previous use of hormonal contraceptives result in a higher PI. IMPLICATIONS: PIs from different clinical trials cannot be meaningfully compared unless subject characteristics that have most impact on the PI are similar or are made to be similar statistically as we did here by matching.
OBJECTIVE: To examine the impact of subject characteristics on efficacy as measured by the Pearl Index (PI) in clinical trials and to make study populations similar by matching. METHODS: Our analysis used US data from four large Phase III studies. We compared results from one fertility control patch study with pooled data from three studies with virtually identical design on oral hormonal contraceptives. First, we identified three characteristics that had the most impact on the PI. Second, we used these three variables and matched subjects from the patch study with those from the oral contraceptive (OC) studies. Finally, we calculated the PIs for matched and unmatched subjects from both the patch study and the OC studies. RESULTS: A total of 3706 subjects were included in our analysis. The variables 'Hispanic ethnicity', 'previous pregnancy' and 'previous use of hormonal contraceptives' had the most impact on the PI. The PIs for the matched patch cohort and the matched OC cohort were 2.97 and 2.48, respectively. Those for the unmatched patch cohort and the unmatched OC cohort were 10.17 and 0.90, respectively. CONCLUSION: Subject characteristics strongly influence the PI in clinical studies of hormonal contraceptives. In particular, Hispanic ethnicity, previous pregnancies and no previous use of hormonal contraceptives result in a higher PI. IMPLICATIONS: PIs from different clinical trials cannot be meaningfully compared unless subject characteristics that have most impact on the PI are similar or are made to be similar statistically as we did here by matching.
Authors: C Gerlinger; J Endrikat; E A van der Meulen; T O M Dieben; B Düsterberg Journal: Eur J Contracept Reprod Health Care Date: 2003-06 Impact factor: 1.848
Authors: Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen Journal: J Fam Plann Reprod Health Care Date: 2012-04
Authors: Katarzyna Piotrowska; Christina Wang; Ronald S Swerdloff; Peter Y Liu Journal: Lancet Diabetes Endocrinol Date: 2016-02-23 Impact factor: 44.867
Authors: David F Archer; Ruth B Merkatz; Luis Bahamondes; Carolyn L Westhoff; Philip Darney; Dan Apter; Jeffrey T Jensen; Vivian Brache; Anita L Nelson; Erika Banks; György Bártfai; David J Portman; Marlena Plagianos; Clint Dart; Narender Kumar; George W Creasy; Regine Sitruk-Ware; Diana L Blithe Journal: Lancet Glob Health Date: 2019-06-20 Impact factor: 26.763